Q1 EPS Estimate for Solid Biosciences Increased by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Solid Biosciences in a note issued to investors on Sunday, February 23rd. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.81). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.46) EPS and FY2026 earnings at ($1.54) EPS.

Several other equities research analysts also recently commented on SLDB. JMP Securities assumed coverage on Solid Biosciences in a report on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 price objective for the company. JPMorgan Chase & Co. cut their price target on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Wedbush initiated coverage on Solid Biosciences in a report on Friday, December 13th. They set an “outperform” rating and a $16.00 target price for the company. Citizens Jmp raised Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Chardan Capital lifted their target price on Solid Biosciences from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Nine research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.40.

Solid Biosciences Stock Performance

NASDAQ SLDB opened at $5.29 on Wednesday. The company has a market cap of $214.66 million, a PE ratio of -1.74 and a beta of 2.01. Solid Biosciences has a 12 month low of $2.88 and a 12 month high of $15.05. The stock has a 50 day moving average of $3.89 and a 200-day moving average of $5.71.

Institutional Trading of Solid Biosciences

A number of hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Solid Biosciences by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock valued at $53,000 after purchasing an additional 2,986 shares in the last quarter. Rhumbline Advisers lifted its stake in Solid Biosciences by 10.5% in the fourth quarter. Rhumbline Advisers now owns 43,677 shares of the company’s stock valued at $175,000 after buying an additional 4,161 shares during the period. Wellington Management Group LLP lifted its stake in Solid Biosciences by 4.0% in the fourth quarter. Wellington Management Group LLP now owns 124,551 shares of the company’s stock valued at $498,000 after buying an additional 4,747 shares during the period. Geode Capital Management LLC lifted its stake in Solid Biosciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 509,802 shares of the company’s stock valued at $2,040,000 after buying an additional 4,932 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of Solid Biosciences by 12.3% during the fourth quarter. American Century Companies Inc. now owns 46,857 shares of the company’s stock valued at $187,000 after acquiring an additional 5,126 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Solid Biosciences news, COO David T. Howton sold 5,072 shares of Solid Biosciences stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $28,403.20. Following the transaction, the chief operating officer now owns 15,663 shares in the company, valued at $87,712.80. The trade was a 24.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Alexander Cumbo sold 11,114 shares of Solid Biosciences stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $62,238.40. Following the completion of the transaction, the chief executive officer now owns 38,484 shares in the company, valued at approximately $215,510.40. This represents a 22.41 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,069 shares of company stock worth $137,301. Company insiders own 13.63% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.